Pharmacological Investigation of Anti-obesity Effect of Cyperus Rotundus

According to WHO, obesity is a not unusual place fitness ailment of lipid and carbohydrate metabolism that consequences from immoderate fats accumulation in adipose tissue, liver, skeletal muscle etc. This research was focused on the development and Investigation of Anti-Obesity effect of Cyperus Rotundus in obese rats. The plant- Nagarmotha was collected from Moradabad region and authenticated by the botanist. Firstly, the calibration curve was plotted. Animals were obtained from the animal house maintained at Faculty of Pharmacy, IFTM University, Moradabad, IN. Animals were free to access pellet chow diet and water ad libitum. They were kept as per CPCSEA Guidelines for one week and kept on fasting for 24 hours prior sacrificing the rodents. The rats were divided into 6 groups, each containing 6 animals. It includes Group 1: Normal Diet Control, Group 2: High caloric Diet control (HCD), Group 3: HCD + Orlistat (5 mg/kg), Group 4: HCD + EEN (100 mg/kg), Group 5: HCD+ EEN (200 mg/kg and Group 6: HCD + EEN (300 mg/kg). Each rat was evaluated after the continuous treatments for different parameters such as body weight & food intake, Total Body Electrical Conductivity (TOBEC), blood glucose levels, oral glucose tolerance test, histopathological studies for adipose tissue and liver, RNA Extraction and Semi-Quantitative PCR Analysis and liver and kidney functions test. In results, Ethanolic Extract of Nagarmotha (EEN) at all the three doses- 100mg/kg, 200mg/kg and 300mg/kg significantly exhibited lipid lowering effects when compared to standard group treated with Orlistat and control or high calories diet animals, in all the parameters. The effects were observed in dose-dependent manner, in ascending order with increase in dose. In conclusion, it may be said that EEN is a potential anti-lipidemic agent. This research suggests to characterize and isolate the main moiety responsible for its pharmacological activity (as anti-obesity) and confirm the mode of action- at which receptor subtype binding occurs.